Boston Scientific (NYSE: BSX) today announced positive 12-month study results for its Farapulse pulsed field ablation (PFA) ...

Boston Scientific today shared new clinical data supporting multiple therapies at the Heart Rhythm Society (HRS) 2025 Meeting ...

Emerging pulsed field ablation systems had their moments in the spotlight at the annual meeting of the Heart Rhythm Society ...

Boston Scientific said that while tariffs pose “unfortunate” headwinds—which are poised to add about $200 million to the cost ...

Boston Scientific has reported positive 12-month primary endpoint outcomes from the ADVANTAGE AF trial’s second phase, assessing the Farapulse pulsed field ablation (PFA) system and Farapoint ...

and SAN DIEGO, April 24, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE ... the use of the FARAPULSE™ Pulsed Field Ablation (PFA) System* and adjunctive use of the FARAPOINT ...

Boston Scientific has proven itself to be a fierce ... left atrial appendage closure and atrial fibrillation ablation products. The firm has also acquired adjacent technologies that open the ...

Subjects in the study were monitored using the LUX-Dx insertable cardiac monitor system to detect arrhythmia recurrence.

Boston Scientific (BSX) announced positive 12-month primary endpoint results from the second phase of the ADVANTAGE AF clinical trial ...

Boston Scientific is Thursday's IBD Stock Of The Day. Shares are forming a double-bottom base, while approaching an early entry.

Knavel-Koepsel has acted on the medical advisory board for Boston Scientific ... Many of the limitations of microwave ablation such as risk of thermal injury to surrounding structures, collecting ...

Needham raised its rating on Boston Scientific (NYSE:BSX) from Hold to Buy, setting a new price target of $113, citing ...